AstraZeneca PLC

AZN

Equity

ISIN GB0009895292 / Valor 982352

LSE London Stock Exchange, SETS (2024-11-21)

GBP 100.62+0.93%

AstraZeneca PLC
UMushroom community rating:

4.29 8 votes No rating yet

NegativeNeutralPositive

About company

AstraZeneca PLC is a global pharmaceutical company with a focus on the discovery, development, and commercialization of prescription medicines across various therapy areas. The company is science-led and patient-focused, aiming to address unmet medical needs by bringing innovative medicines to market. AstraZeneca operates in key therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with a growing pipeline in rare diseases. Its business strategy emphasizes growth through innovation, leveraging advanced therapeutic modalities and engaging in strategic partnerships to enhance healthcare outcomes. AstraZeneca's commitment to healthcare extends to improving access to its medicines globally, ensuring it plays a significant role in transforming the future of healthcare.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-1.28%1Y

18.5%3Y

37.2%5Y

Performance

21.4%1Y

23.2%3Y

25.0%5Y

Volatility

196488 M

Market cap (USD)

1,918,869

Daily traded volume (Shares)

100.62 / 98.67

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.29

8 votes

Performance:

4.36

Innovation:

4.36

Society:

3.91

Nature:

3.36

Lou Charlotte Wehrli

Switzerland, 01 Nov 2023

Innovation in healthcare and rare diseases is so important - AstraZeneca is doing a good job at that

Tonia Zimmermann

Switzerland, 01 Nov 2023

One of the few names profiting from the pandemic without giving up all the gains. Well diversified portfolio and strategy.

Laura Bischofberger

Switzerland, 01 Nov 2023

Interessanter Deal mit Cellectis

EQUITIES OF THE SAME SECTOR

Oncopeptides AB

Oncopeptides AB Valor: 35671972

Annual Return

-50%0%+50%

Risk level

110

1.48%SEK 1.51

QuidelOrtho Corporation

QuidelOrtho Corporation Valor: 119356965

Annual Return

-50%0%+50%

Risk level

110

1.09%USD 37.89

Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings Inc Valor: 1262932

Annual Return

-50%0%+50%

Risk level

110

-0.80%USD 108.40

dentalcorp Holdings Ltd

dentalcorp Holdings Ltd Valor: 111405816

Annual Return

-50%0%+50%

Risk level

110

-1.18%CAD 9.24

DocMorris Ltd

DocMorris Ltd Valor: 4261528

Annual Return

-50%0%+50%

Risk level

110

-6.11%CHF 28.90

Savaria Corp

Savaria Corp Valor: 1385257

Annual Return

-50%0%+50%

Risk level

110

0.80%CAD 22.81

Sienna Senior Living Inc

Sienna Senior Living Inc Valor: 28093100

Annual Return

-50%0%+50%

Risk level

110

0.24%CAD 17.03

WELL Health Technologies Corp

WELL Health Technologies Corp Valor: 42769021

Annual Return

-50%0%+50%

Risk level

110

0.58%CAD 5.17

agilon health inc

agilon health inc Valor: 110653729

Annual Return

-50%0%+50%

Risk level

110

6.59%USD 1.78

Terveystalo Oyj

Terveystalo Oyj Valor: 37893402

Annual Return

-50%0%+50%

Risk level

110

-1.61%EUR 9.80

Logos provided by Clearbit

AstraZeneca PLC

AZN

ISIN GB0009895292 / Valor 982352

AstraZeneca PLC UMushroom community rating:

Lou Charlotte Wehrli

Tonia Zimmermann

Laura Bischofberger

AstraZeneca PLC
UMushroom community rating: